BR9908726A - Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um composto - Google Patents

Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um composto

Info

Publication number
BR9908726A
BR9908726A BR9908726-0A BR9908726A BR9908726A BR 9908726 A BR9908726 A BR 9908726A BR 9908726 A BR9908726 A BR 9908726A BR 9908726 A BR9908726 A BR 9908726A
Authority
BR
Brazil
Prior art keywords
compound
processes
diseases
diabetes
type
Prior art date
Application number
BR9908726-0A
Other languages
English (en)
Inventor
Niels Peter Hundahl Moller
Henrik Sune Andersen
Lars Fogh Iversen
Ole Hvilsted Olsen
Sven Branner
Daniel Dale Holsworth
Frarid Bakir
Luke Milburn Judge
Frank Urban Axe
Todd Kevin Jones
William Charles Ripka
Yu Ge
Roy Teruyuki Uyeda
Original Assignee
Novo Nordisk As
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Ontogen Corp filed Critical Novo Nordisk As
Priority claimed from PCT/DK1999/000121 external-priority patent/WO1999046267A1/en
Publication of BR9908726A publication Critical patent/BR9908726A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrodes Of Semiconductors (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Bipolar Transistors (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Control Of El Displays (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, PROCESSOS PARA TRATAMENTO DO DIABETE DO TIPO I E DE DISFUNçõES IMUNES, PARA FABRICAçãO DE UM MEDICAMENTO, E, PARA PREPARAçãO DE UM COMPOSTO". A presente invenção fornece novos compostos, novas composições, processos para seu uso e processo para sua fabricação, onde tais compostos são inibidores farmacologicamente úteis das Tirosina Fosfatases proteínicas (PTPases), tais como PTP1B, CD45, SHP-1, SHP-2, PTP<244>, LAR E HePTP ou coisa parecida. Os compostos são úteis no tratamento do diabete tipo I, diabete tipo II, tolerância à glicose prejudicada, resistência à insulina, obesidade, disfunções imunes incluindo as doenças de autoimunidade com disfunções do sistema de coagulação, doenças alérgicas incluindo a asma, a osteosporose, os distúrbios proliferativos incluindo o câncer e a psoríase, doenças com síntese reduzida ou aumentada ou efeitos do hormónio do crescimento, doenças com síntese reduzida ou aumentada de hormónios ou citocinas que regulam a liberação do/ou a resposta ao, hormónio do crescimento, doenças do cérebro incluindo a doença de Alzheimer e a esquizofrenia, e doenças infecciosas.
BR9908726-0A 1998-03-12 1999-03-11 Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um composto BR9908726A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DK34498 1998-03-12
DK48098 1998-04-03
DKPA199800938 1998-07-15
DKPA199801385 1998-10-28
DKPA199801612 1998-12-07
PCT/DK1999/000121 WO1999046267A1 (en) 1998-03-12 1999-03-11 Modulators of protein tyrosine phosphatases (ptpases)

Publications (1)

Publication Number Publication Date
BR9908726A true BR9908726A (pt) 2000-11-21

Family

ID=27512769

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908726-0A BR9908726A (pt) 1998-03-12 1999-03-11 Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um composto

Country Status (13)

Country Link
EP (1) EP1080095B1 (pt)
JP (1) JP2002506072A (pt)
KR (1) KR20010041814A (pt)
CN (1) CN1300291A (pt)
AT (1) ATE308546T1 (pt)
AU (1) AU2713599A (pt)
BR (1) BR9908726A (pt)
CA (1) CA2323493A1 (pt)
DE (1) DE69928100D1 (pt)
HU (1) HUP0104984A3 (pt)
IL (1) IL138319A0 (pt)
NO (1) NO20004527L (pt)
PL (1) PL342816A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847263A3 (en) 2000-12-18 2009-08-26 Institute of Medicinal Molecular Design, Inc. Inhibitors against the production and release of inflammatory cytokines
EA008769B1 (ru) * 2002-06-05 2007-08-31 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения диабета
EA009523B1 (ru) * 2002-06-05 2008-02-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Ингибиторы в отношении активации ар-1 и nfat
CN1658872B (zh) 2002-06-06 2010-09-22 株式会社医药分子设计研究所 抗过敏药
TW200406198A (en) 2002-06-06 2004-05-01 Inst Med Molecular Design Inc O-substituted hydroxyaryl derivatives
PL1753512T3 (pl) * 2004-05-28 2009-03-31 4Sc Ag Tetrahydropirydotiofeny
JP2008501668A (ja) * 2004-06-04 2008-01-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療に使用するためのテトラヒドロピリドチオフェン
WO2005120642A2 (en) * 2004-06-11 2005-12-22 Altana Pharma Ag Tetrahydropyridothiophenes for treating hyperproliferative disorders
CN101891680B (zh) * 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
CA2596202A1 (en) * 2005-02-09 2006-08-17 Altana Pharma Ag Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
US7741488B2 (en) * 2005-02-11 2010-06-22 4Sc Ag Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer
JP4908511B2 (ja) * 2005-09-15 2012-04-04 エフ．ホフマン−ラ ロシュ アーゲー ４−アミノ−チエノ［３，２−ｃ］ピリジン−７−カルボン酸誘導体
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
PT3252057T (pt) * 2009-12-04 2024-06-04 Sunovion Pharmaceuticals Inc Compostos multicíclicos e métodos de utilização dos mesmos
CN102382076B (zh) * 2010-09-03 2016-08-17 中国医学科学院药物研究所 芳酮和芳酰胺类化合物及其制法和药物用途
CN102838625B (zh) * 2011-06-22 2015-04-15 中国科学院上海药物研究所 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途
JP6409004B2 (ja) * 2013-01-28 2018-10-17 ハー・ルンドベック・アクチエゼルスカベット ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸
CN104788425A (zh) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺和哌啶结构ptp1b抑制剂、制备方法及其用途
CN104788424A (zh) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途
CN106866523A (zh) * 2015-03-12 2017-06-20 佛山市赛维斯医药科技有限公司 含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途
CN106748999A (zh) * 2015-03-12 2017-05-31 佛山市赛维斯医药科技有限公司 一类含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途
CN104829629B (zh) * 2015-03-26 2017-03-15 天津药物研究院有限公司 含磺酰胺基的四氢噻吩并[2,3‑c]吡啶衍生物、其制备方法和用途
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
CN116808023A (zh) 2017-02-16 2023-09-29 桑诺维恩药品公司 治疗精神分裂症的方法
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
WO2020233645A1 (zh) 2019-05-21 2020-11-26 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
EP4135711A4 (en) * 2020-04-14 2024-05-29 Purdue Research Foundation LYMPHOID-SPECIFIC TYROSINE PHOSPHATASE INHIBITORS
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders

Also Published As

Publication number Publication date
PL342816A1 (en) 2001-07-02
IL138319A0 (en) 2001-10-31
JP2002506072A (ja) 2002-02-26
KR20010041814A (ko) 2001-05-25
ATE308546T1 (de) 2005-11-15
CA2323493A1 (en) 1999-09-16
CN1300291A (zh) 2001-06-20
EP1080095B1 (en) 2005-11-02
NO20004527D0 (no) 2000-09-11
HUP0104984A3 (en) 2003-07-28
AU2713599A (en) 1999-09-27
EP1080095A1 (en) 2001-03-07
NO20004527L (no) 2000-11-07
DE69928100D1 (de) 2005-12-08
HUP0104984A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
NO20004527D0 (no) Modulatorer for proteintyrosinfosfataser (PTPaser)
BRPI0411484A (pt) composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica
DE69807349T2 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
Wei et al. Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE2, and MMP-13 expression
BR0212512A (pt) Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
BRPI0409447A (pt) ácidos fenilalcanóicos substituìdos
BR0314577A (pt) Derivados de triazol como inibidores do fator de crescimento de transformação (tgf)
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BRPI0414488A (pt) derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti - proliferativo em um animal de sangue quente, para prevenção ou tratamento de tumores em um aminal de sangue quente, para fornecer um efeito inibidor da tirosina quinase de egfr seletivo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e, processo para a preparação de um derivado de quinazolina
Ciobanu et al. Acute and chronic effects of neurotrophic factors BDNF and GDNF on responses mediated by thermo-sensitive TRP channels in cultured rat dorsal root ganglion neurons
BRPI0510664B8 (pt) derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios
Olianas et al. Inhibition of TNF-α-induced neuronal apoptosis by antidepressants acting through the lysophosphatidic acid receptor LPA1
BR9815596A (pt) Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase
Farid et al. Preparation of bee venom-loaded chitosan nanoparticles for treatment of streptozotocin-induced diabetes in male Sprague Dawley rats
Pelc et al. Incorporation of labelled thymidine in the seminal vesicle of the mouse
Aleem et al. History and Traditional uses of Tiryaq (Theriac): An important formulation in Unani medicine
BRPI0606388A2 (pt) composto, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto
KR101920152B1 (ko) 면역증진 효과가 있는 녹용약침 및 이의 조제방법
Sabi et al. Anti-inflammatory and anti-hyperuricemic effect of Ficus benghalensis bark extract in raw 246.7 cell line
Yen et al. Glycine tomentella Hayata inhibits IL-1β and IL-6 production, inhibits MMP-9 activity, and enhances RAW264. 7 macrophage clearance of apoptotic cells
AU734887B2 (en) Therapeutic agent and treatment for canine intractable dermatitis
CN108245500A (zh) 王浆酸在制备治疗腺苷脱氨酶活性升高的疾病药中的用途
Yadav et al. Therapeutic Action of Capsaicin in the Management of Pain in Osteoarthritis
AU2016256704B2 (en) Pharmaceutical composition increasing cyclic AMP content and availability in vivo, and preparation method thereof
Niswara et al. Utilizing Water Hyacinth (Eichhornia crassipes) from Srandakan Bantul, Indonesia for ‘Bright Fever Patch’as an Alternative Children’s Fever Therapy

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTA A 5O, 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.